Trials / Completed
CompletedNCT03678454
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Prospective Registry of Iclusig® (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Incyte Biosciences Benelux · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
Conditions
Timeline
- Start date
- 2017-02-03
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2018-09-19
- Last updated
- 2022-04-12
Locations
19 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03678454. Inclusion in this directory is not an endorsement.